New obesity drug receives US approval, challenging competitors
Eli Lilly has announced that its new drug 'Foundio' has received approval from the US Food and Drug Administration, paving the way for strong competition in the oral obesity medication market. This development comes as companies strive to provide effective solutions to the global obesity crisis.